DDInter1335 DDInter1652
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Omacetaxine mepesuccinate {u} (Compound) binds {v} (Gene) RPL3
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) DUSP8
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) B4GAT1
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rituximab
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Indomethacin
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Omacetaxine mepesuccinate (Compound) binds RPL3 (Gene)
Omacetaxine mepesuccinate (Compound) upregulates DUSP8 (Gene)
Omacetaxine mepesuccinate (Compound) downregulates B4GAT1 (Gene)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Rituximab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Indomethacin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib